Histological Changes Observed in Placentas Exposed to Medication-Assisted Treatment
Table 1
Maternal demographics and neonatal outcomes of MAT-exposed gestations compared with uncomplicated gestational age-matched controls.
Buprenorphine
Methadone
MAT
Controls
Maternal
Maternal age (years)
BMI (kg/m2)
Race
Caucasian
38 (93)
54 (87)
92 (89)
25 (63)
Black
2 (5)
1 (2)
3 (3)
2 (5)
Hispanic
1 (2)
3 (5)
4 (4)
9 (23)
Other
0 (0)
1 (2)
1 (1)
3 (8)
Smoker
18 (44)
38 (61)
56 (54)
7 (17)
GA delivery (weeks)
39 (34-42)
39 (34-41)‡
39 (34-42)
39 (35-42)
4 (10)
10 (16)
14 (14)
3 (8)
Neonatal
Birth weight (grams)
Small for gestational age
4 (10)
4 (6)
8 (8)
3 (8)
5-minute Apgar score
LOS hospital (days)
Required morphine
13 (32)
30 (48)
43 (42)
0 (0)
Respiratory distress
8 (20)
19 (31)
27 (26)
5 (13)
Categorical data presented as (%) and continuous data presented as the or median (range). BMI: body mass index; GA: gestational age; MAT: medication-assisted treatment; LOS: length of stay. compared with the control group. ‡ buprenorphine group compared the methadone group.
